Match!
Gary E. Raskob
University of Oklahoma Health Sciences Center
286Publications
73H-index
31.8kCitations
Publications 298
Newest
#1Jeffrey I. Weitz (McMaster University)H-Index: 90
#2Gary E. Raskob (OU: University of Oklahoma)H-Index: 73
Last.Haitao Yang (Janssen Pharmaceutica)
view all 13 authors...
Source
#1Jeffrey I. Weitz (McMaster University)H-Index: 90
#2Rupert BauersachsH-Index: 27
Last.Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 8 authors...
Importance The efficacy of factor XIa inhibition for thromboprophylaxis is unknown. Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa. Objective To compare different doses of osocimab with enoxaparin and apixaban for thromboprophylaxis in patients who have undergone knee arthroplasty. Design, Setting, and Participants Randomized, open-label, adjudicator-blinded, phase 2 noninferiority trial with observer blinding for osocimab doses, conducted at 54 hospitals in ...
1 CitationsSource
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Nick van Es (UvA: University of Amsterdam)H-Index: 17
Last.Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 21 authors...
Abstract Background The safety and efficacy of edoxaban and dalteparin is unclear for several cancer groups. Methods We evaluated the occurrence of the primary outcome in large cancer groups. The primary outcome was the composite of recurrent VTE or major bleeding over 12 months. Results In patients with gastrointestinal cancer, the primary outcome occurred in 19.4% patients given edoxaban and in 15.0% given dalteparin (risk difference [RD], 4.4%; 95%-CI, −4.1% to 12.8%). The corresponding rates...
1 CitationsSource
#1Jeffrey I. Weitz (McMaster University)H-Index: 90
#2Annelise SegersH-Index: 16
Last.John Strony (Janssen Pharmaceutica)H-Index: 23
view all 13 authors...
Source
#1Thita Chiasakul (Chula: Chulalongkorn University)H-Index: 3
#2Christina R. Evans (UPenn: University of Pennsylvania)
Last.Adam Cuker (UPenn: University of Pennsylvania)H-Index: 32
view all 6 authors...
Source
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Marcello Di NisioH-Index: 30
Last.Nick van Es (UvA: University of Amsterdam)H-Index: 17
view all 17 authors...
Introduction In cancer patients, current guidance suggests similar treatment for incidental and symptomatic venous thromboembolism (VTE), mainly based on retrospective data. We aimed to evaluate anticoagulant therapy in cancer patients with incidental and symptomatic VTE. Methods The Hokusai VTE Cancer study was a randomised controlled trial comparing edoxaban with dalteparin for cancer-associated VTE. The primary outcome was the composite of first recurrent VTE or major bleeding. Secondary outc...
Source
#1Alex C. Spyropoulos (The Feinstein Institute for Medical Research)H-Index: 1
#2Walter Ageno (University of Insubria)H-Index: 8
Last.Elliot S. Barnathan (Janssen Pharmaceutica)H-Index: 15
view all 15 authors...
Source
#1Micah McCumber (University of Oklahoma Health Sciences Center)H-Index: 7
#2Aaron M. Wendelboe (University of Oklahoma Health Sciences Center)H-Index: 18
Last.Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 7 authors...
Source
#1Alys Adamski (CDC: Centers for Disease Control and Prevention)H-Index: 3
#2Aaron M. Wendelboe (University of Oklahoma Health Sciences Center)H-Index: 18
Last.Michele G. BeckmanH-Index: 9
view all 8 authors...
Source
#1Alex C. Spyropoulos (The Feinstein Institute for Medical Research)H-Index: 1
#2Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
Last.Elliot S. Barnathan (Janssen Pharmaceutica)H-Index: 15
view all 9 authors...
Source
12345678910